{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:19:52Z","timestamp":1788265192654,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic hepatitis B (CHB) caused by HBV infection leads to persistent liver inflammation. PEG IFN\u03b1-2b shows higher functional cure rates than oral antivirals, but identifying optimal candidates remains challenging. This study evaluates serum ferritin as a predictive biomarker for PEG IFN\u03b1-2b efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum ferritin, HBsAg and transaminase were monitored in CHB patients treated with PEG IFN \u03b1-2b at baseline (0w), 12w and 24w. Patients were divided into the effective group (HBsAg reduction \u22651 log10 IU\/mL or clearance) and the ineffective group (HBsAg reduction &amp;lt;1 log10 IU\/mL) at 24 weeks. Similarly, for the results at 48 weeks, the patients were divided into the clearance group (achieving HBsAg clearance) and the non-clearance group (not achieving HBsAg clearance). To analyze the correlation between serum ferritin and the decrease of HBsAg, a multivariate logistic regression model was constructed. Potential confounding factors such as age, gender, HBeAg and HBV DNA status, ALT, AST, and iron metabolism indicators (FE, TIBC, TS) were included to evaluate the independent predictive effect of ferritin levels on the therapeutic effectiveness, calculate the corrected OR value and 95% CI. The predictive effect was evaluated by the ROC curve.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among patients with chronic hepatitis B (CHB) who completed the PEG IFN\u03b1-2b course of treatment, the serum ferritin levels of all patients showed an increasing trend at baseline and during the treatment process, and the serum ferritin level in the effective treatment group (HBsAg reduction \u22651 log10 IU\/mL or clearance) was significantly higher than that in the ineffective treatment group. It was confirmed by Spearman\u2019s rank correlation analysis that the serum ferritin level was positively correlated with the decrease in HBsAg. Further analysis through the multivariate logistic regression model revealed that serum ferritin remained an independent predictor of the antiviral efficacy of PEG IFN\u03b1-2b. ROC curve analysis indicated that serum ferritin had a high predictive value for the antiviral efficacy of PEG IFN\u03b1-2b.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The level of serum ferritin is closely related to the anti-hepatitis B virus efficacy of PEG IFN\u03b1-2b. It has great potential as a reliable and economical biomarker to guide treatment and optimize treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1603286","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:07:41Z","timestamp":1757311661000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum ferritin as a predictive biomarker for PEG IFN\u03b1-2b efficacy in chronic hepatitis B treatment"],"prefix":"10.3389","volume":"15","author":[{"given":"Meiya","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3949\/ccjm.85a.17103","article-title":"Liver enzymes: no trivial elevations, even if asymptomatic","volume":"85","author":"Agganis","year":"2018","journal-title":"Cleve. Clin. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood-2009-11-253815","article-title":"Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway","volume":"116","author":"Cohen","year":"2010","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00116","article-title":"The role of iron regulation in immunometabolism and immune-related disease","volume":"6","author":"Cronin","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28237707","article-title":"New perspectives on circulating ferritin: its role in health and disease","volume":"28","author":"Fonseca","year":"2023","journal-title":"Molecules"},{"key":"B6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jhep.2023.09.039","article-title":"Higher tp53bp2 expression is associated with hbsag loss in peginterferon-A-treated patients with chronic hepatitis B","volume":"80","author":"Guan","year":"2024","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12887-022-03482-0","article-title":"The efficacy of pegylated interferon alpha-2a and entecavir in hbeag-positive children and adolescents with chronic hepatitis B","volume":"22","author":"He","year":"2022","journal-title":"BMC Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/liv.12081","article-title":"Management of acute hepatitis B and reactivation of hepatitis B","author":"Jindal","year":"2013","journal-title":"Liver. Int."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h3692","article-title":"Interpreting raised serum ferritin levels","volume":"351","author":"Koperdanova","year":"2015","journal-title":"Bmj"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/apt.14636","article-title":"Impact of hbv genotype and mutations on hbv DNA and qhbsag levels in patients with hbeag-negative chronic hbv infection","volume":"47","author":"Kuhnhenn","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/hep.24787","article-title":"Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy","volume":"55","author":"Lange","year":"2012","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.12787","article-title":"Precore\/core promoter variants to predict significant fibrosis in both hbeag positive and negative chronic hepatitis B","volume":"35","author":"Lapalus","year":"2015","journal-title":"Liver. Int."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105584","article-title":"Mir-548c-3p targets trim22 to attenuate the peg-ifn-A Therapeutic efficacy in hbeag-positive patients with chronic hepatitis B","volume":"213","author":"Lin","year":"2023","journal-title":"Antiviral Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e28183","DOI":"10.1002\/jmv.28183","article-title":"Serum ferritin diagnosis and prediction of hepatitis B virus-related acute-on-chronic liver failure","volume":"95","author":"Luo","year":"2023","journal-title":"J. Med. Virol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25081997","article-title":"Viral hepatitis and iron dysregulation: molecular pathways and the role of lactoferrin","volume":"25","author":"Mancinelli","year":"2020","journal-title":"Molecules"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.816282","article-title":"Iron metabolism and immune regulation","volume":"13","author":"Ni","year":"2022","journal-title":"Front. Immunol."},{"key":"B17","unstructured":"Hepatitis B: World Health Organization\n          \n          \n          \n          2025"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779347","article-title":"Pegylated interferon treatment for the effective clearance of hepatitis B surface antigen in inactive hbsag carriers: A meta-analysis","volume":"12","author":"Song","year":"2021","journal-title":"Front. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1182\/blood.v99.10.3505","article-title":"Regulation of ferritin genes and protein","volume":"99","author":"Torti","year":"2002","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1136\/gutjnl-2024-332290","article-title":"Hbcrag values may predict virological and immunological responses to pegifn-A in nuc-suppressed hbeag-negative chronic hepatitis B","volume":"73","author":"Vecchi","year":"2024","journal-title":"Gut"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13099-021-00421-9","article-title":"Potential capacity of interferon-A to eliminate covalently closed circular DNA (Cccdna) in hepatocytes infected with hepatitis B virus","volume":"13","author":"Wang","year":"2021","journal-title":"Gut. Pathog."},{"key":"B22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12985-024-02368-0","article-title":"Lower hbv DNA level is associated with more severe liver fibrosis in hbeag-positive chronic hepatitis B with normal alanine transaminase","volume":"21","author":"Wang","year":"2024","journal-title":"Virol. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of hbv: stopping nucs, adding interferon or new drug development","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0122259","DOI":"10.1371\/journal.pone.0122259","article-title":"Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients","volume":"10","author":"Yeh","year":"2015","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6030085","article-title":"A short review of iron metabolism and pathophysiology of iron disorders","volume":"6","author":"Yiannikourides","year":"2019","journal-title":"Medicines (Basel)."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2259003","article-title":"The presence of baseline hbsab-specific B cells can predict hbsag or hbeag seroconversion of chronic hepatitis B on treatment","volume":"12","author":"Yin","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/jcth.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (Version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.14218\/jcth.2020.00136","article-title":"Significant histologic changes are not rare in treatment-naive hepatitis B patients with normal alanine aminotransferase level: A meta-analysis","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2531","DOI":"10.1002\/rmv.2531","article-title":"Ferritin: significance in viral infections","volume":"34","author":"Zhao","year":"2024","journal-title":"Rev. Med. Virol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1603286\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:07:44Z","timestamp":1757311664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1603286\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":29,"alternative-id":["10.3389\/fcimb.2025.1603286"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1603286","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"article-number":"1603286"}}